Eli Lilly (LLY) news

Older LLY news events, each with the realized, point-in-time move the market made — page 7 of 8. Back to the LLY overview → · Full LLY reaction history →

Latest news

Recent LLY events, each with its measured reaction. (Page 7 of 8.)

DateHeadlineEventSource5-minTo close
New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitisPress releasePR Newswire+0.45%-0.77%
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's DiseasePress releasePR Newswire-0.09%+0.25%
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic DermatitisPress releasePR Newswire-0.79%-0.62%
Lilly expands manufacturing footprint in Ireland with $1.8 billion investmentPress releasePR Newswire-0.30%+1.16%
Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetesPress releasePR Newswire-0.17%-0.38%
With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetesPress releasePR Newswire-0.16%+0.21%
Form 8-K ELI LILLY & Co For: Sep 05SEC filing · Form 8-KSEC EDGAR-0.06%-0.54%
Lilly appoints Lucas Montarce as executive vice president and chief financial officerPress releasePR Newswire-0.06%-0.54%
In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulinPress releasePR Newswire-0.43%-3.02%
Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countriesPress releasePR Newswire-0.68%-0.48%
Lilly Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for OMVOH® (mirikizumab) for adults with moderately to severely active ulcerative colitis (UC)Press releaseCanada Newswire-0.09%-0.13%
Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesityPress releasePR Newswire+0.51%+0.21%
Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare ConferencePress releasePR Newswire+0.70%-1.15%
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweightPress releasePR Newswire+1.61%+1.93%
Form 8-K ELI LILLY & Co For: Aug 13SEC filing · Form 8-KSEC EDGAR-0.34%-0.03%
Lilly announces retirement of Marschall S. Runge from its Board of DirectorsPress releasePR Newswire-0.34%-0.03%
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel DiseasePress releasePR Newswire-0.31%-0.68%
Form 8-K/A LL Flooring Holdings, For: Aug 07SEC filing · Form 8-KSEC EDGAR-0.31%-0.68%
Form 8-K ELI LILLY & Co For: Aug 12SEC filing · Form 8-KSEC EDGAR+0.11%+0.65%
Lilly opens state-of-the-art research and development center in the Boston SeaportPress releasePR Newswire+0.08%+1.46%
Form 10-Q ELI LILLY & Co For: Jun 30SEC filing · Form 10-QSEC EDGAR+0.17%+1.59%
Form 8-K ELI LILLY & Co For: Aug 08SEC filing · Form 8-KSEC EDGAR-2.75%-3.17%
Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 BillionPress releasePR Newswire-2.75%-3.17%
Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesityPress releasePR Newswire-0.87%-0.04%
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results AnnouncementPress releasePR Newswire-0.65%-1.07%
Form 8-K ELI LILLY & Co For: Jul 05SEC filing · Form 8-KSEC EDGAR-0.07%+0.34%
GordonMD® Global Investments Portfolio Company, Radionetics Oncology, Announced Strategic Agreement with LillyPress releaseBusiness Wire-0.30%+0.25%
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel DiseasePress releasePR Newswire-0.30%+0.25%
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's DiseasePress releasePR Newswire+0.33%+0.61%
Health Canada Authorizes Lilly's Ebglyss™ (lebrikizumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents 12 Years and OlderPress releaseCanada Newswire-0.14%+0.99%
Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteriaPress releasePR Newswire+0.20%+1.08%
Form 11-K ELI LILLY & Co For: Dec 31SEC filing · Form 11-KSEC EDGAR-0.14%+0.99%
Lilly Declares Third-Quarter 2024 DividendPress releasePR Newswire-0.07%-0.79%
LILLY'S TIRZEPATIDE REDUCED OBSTRUCTIVE SLEEP APNEA (OSA) SEVERITY, WITH UP TO 51.5% OF PARTICIPANTS MEETING THE CRITERIA FOR DISEASE RESOLUTIONPress releaseCanada Newswire-0.07%-0.79%
Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolutionPress releasePR Newswire+0.29%+0.16%
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs RisesPress releaseGlobeNewswire-2.08%-1.61%
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeksPress releasePR Newswire-0.34%+1.29%
Form 8-K ELI LILLY & Co For: Jun 02SEC filing · Form 8-KSEC EDGAR-0.34%+0.21%
Lilly announces departure of Anat Ashkenazi, chief financial officerPress releasePR Newswire-0.34%+0.21%
Melissa Seymour to join Lilly as executive vice president of Global QualityPress releasePR Newswire-0.89%-0.21%
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual MeetingPress releasePR Newswire+0.55%+1.44%
Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseasesPress releasePR Newswire+0.34%+0.78%
Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare ConferencePress releasePR Newswire+0.13%+2.14%
Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline MedicinesPress releasePR Newswire+0.01%-0.07%
Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingPress releasePR Newswire+0.01%-0.07%
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failurePress releasePR Newswire+1.91%+1.15%
With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily InsulinPress releasePR Newswire-0.09%-1.84%
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance OfficerPress releasePR Newswire+0.12%+2.99%
Form 8-K ELI LILLY & Co For: May 06SEC filing · Form 8-KSEC EDGAR-0.01%-1.92%
Lilly Declares Second-Quarter 2024 DividendPress releasePR Newswire-0.09%+2.13%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground